Skip to main content

Table 5 Demographic information of monocyte tolerance studies

From: Uncontrolled sepsis: a systematic review of translational immunology studies in intensive care medicine

Author

Age

Gender (%male)

Subject ethnicity

Severity of subject disease

Subject drug exposure documentation

Subjects

Controls

Statistical test result

Subjects

Controls

Statistical test result

Index

Score

No. of groups

Sedatives

Antibiotics

Steroids

Liu [30]

?

?

N

?

?

N

N

?

?

1

N

N

N

Buttenschoen [41]

56 (33 to 88)

N/A

N

70

N/A

N

N

?

?

n/a

N

N

N

Pachot [31]

68 (54 to 76)

51 (42 to 65)

N

62

52

N

N

SAPS II

51 (±5)

2

N

N

N

West [32]

N/S

N/S

N

42

100; 20; 56

N

N

?

?

2

N

N

N

Harter [33]

48 ± 20

'Comparable’

N

71

12

N

N

APACHE II

13 ± 6

1

N”

N

N

Flohe [40]

47 ± 18

37 ± 14

N

68

50

N

N

ISS

39 ± 9

1

N

N

N

Escoll [34]

51 ± 12

49 ± 12

N

?

?

N

N

?

?

1

N

N

N

Heagy [39]

49 ± 3; 44 ± 8

?

N

?

?

N

N

Mortality

20%, 9.6%

2

N

N

N

Calvano [35]

60; 61

58

N

66; 66

66

N

N

?

?

2

N

N

Yt

Sfeir [36]

63 ± 3

50 ± 7

N* (p < 0.0001)

80

50

N

N

APACHE II

27 ± 5

1

N

N

N

Kawasaki [42]

?

N/A

N

?

N/A

N

N

ASA

I to II

1

N

N

N

Heagy [37]

49 ± 21

?

N

66

?

N

N

?

?

4

N

N

N

Bergmann [38]

60; 51

32

N

?

?

N

N

MODS

15 ± 1, 7 ± 1

2

N

N

N

  1. Age: N/S, not summarised (tabulated data for every patient provided); question mark (?), not provided within the manuscript; N/A, not applicable. Statistical test result: N, not reported; N*, not reported but we identified the significant p value from the original manuscript data. Severity of subject disease: The average clinical severity score of subjects with an index of spread listed in brackets. The number of severity groups which subjects were divided into is listed. ISS/AIS, Injury Severity Score/Abbreviated Injury Severity Score [87]; ASA, American Society of Anesthesiologists Physical Status Classification System [85]; APACHE II: Acute Physiology and Chronic Health Evaluation II [83], APACHE III, Acute Physiology and Chronic Health Evaluation III [84]. Subject drug use detailed: whether patient exposure to known immunomodulating drugs was documented. A‘t’ signifies that the timing of the drug administration in relation to blood sampling was clear from the study methodology.